Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Obesity defined molecular endotypes in the synovium of patients with osteoarthritis provides a rationale for therapeutic targeting of fibroblast subsets
10.1016/j.bbrc.2024.149788 46 GaoW.WangW.LiuG.ZhangJ.YangJ.DengZ
doi: 10.3389/fncel.2024.1426231 Received 01 May 2024 Accepted 14 June 2024 Published 05 August 2024 Volume 18 - 2024 Edited by Wensheng Lin, University of Minnesota Twin Cities, United States Reviewed by Zhixin Lei, Wuhan University of Technology, China Carlos Matute, Achucarro Basque Center for Neuroscience, Spain Updates Copyright 2024 Stys, Tsutsui, Gafson, t Hart, Belachew and Geurts
Temporary sleep disruption does not reflect treatment effectiveness
Is it okay to drink milk while taking glutathione
82 HP 175 IGF-1 LR3 Long R3 IGF-1 extended half-life anabolic research compound ALIASES Long R3 IGF-1, LR3 IGF-1, IGF-1LR3, IGF1 LR3 CLASS Synthetic 83-residue insulin-like growth factor 1 analog FORMULA C400H625N111O115S9 HALF-LIFE ~6 hours (vs ~10 minutes native IGF-1) ROUTES Subcutaneous (research) MECHANISM OF ACTION Long R3 Insulin-like Growth Factor 1 83-residue synthetic analog of native IGF-1 with N-terminal 13-residue extension and Arg substitution at position 3
